Transition to dolutegravir-based ART in 35 low- and middle-income countries: a global survey of HIV care clinics.

IF 3.4 2区 医学 Q3 IMMUNOLOGY AIDS Pub Date : 2024-09-05 DOI:10.1097/QAD.0000000000004007
Elizabeth Zaniewski, Veronika Whitesell Skrivankova, Ellen Brazier, Anchalee Avihingsanon, Sandra Wagner Cardoso, Carina Cesar, Henri Chenal, Brenda E Crabtree-Ramírez, Rossana A Ditangco, Peter Vanes Ebasone, Brian Eley, Jonathan George Euvrard, Geoffrey Fatti, Jacqueline Madalitso Huwa, Patricia Lelo, Daisy Maria Machado, Eugene Kouassi Messou, Albert Kla Minga, Joseph Muleebwa, Sanjay Mundhe, Gad Murenzi, Winnie R Muyindike, Dominique Mahambou Nsonde, Sarah M Obatsa, Joseph Odhiambo, Hans Walter Prozesky, Supattra Rungmaitree, Aggrey Semwendero Semeere, Moussa Seydi, Nosisa Sipambo, Tavitiya Sudjaritruk, Karl-Günter Technau, Thierry Tiendrebeogo, Christelle Twizere, Marie Ballif
{"title":"Transition to dolutegravir-based ART in 35 low- and middle-income countries: a global survey of HIV care clinics.","authors":"Elizabeth Zaniewski, Veronika Whitesell Skrivankova, Ellen Brazier, Anchalee Avihingsanon, Sandra Wagner Cardoso, Carina Cesar, Henri Chenal, Brenda E Crabtree-Ramírez, Rossana A Ditangco, Peter Vanes Ebasone, Brian Eley, Jonathan George Euvrard, Geoffrey Fatti, Jacqueline Madalitso Huwa, Patricia Lelo, Daisy Maria Machado, Eugene Kouassi Messou, Albert Kla Minga, Joseph Muleebwa, Sanjay Mundhe, Gad Murenzi, Winnie R Muyindike, Dominique Mahambou Nsonde, Sarah M Obatsa, Joseph Odhiambo, Hans Walter Prozesky, Supattra Rungmaitree, Aggrey Semwendero Semeere, Moussa Seydi, Nosisa Sipambo, Tavitiya Sudjaritruk, Karl-Günter Technau, Thierry Tiendrebeogo, Christelle Twizere, Marie Ballif","doi":"10.1097/QAD.0000000000004007","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>We studied the transition to dolutegravir-containing antiretroviral therapy (ART) at HIV treatment clinics within the International epidemiology Databases to Evaluate AIDS (IeDEA).</p><p><strong>Design: </strong>Site-level survey conducted in 2020-2021 among HIV clinics in low- and middle-income countries (LMICs).</p><p><strong>Methods: </strong>We assessed the status of dolutegravir rollout and viral load and drug resistance testing practices for patients on ART switching to dolutegravir-based regimens. We used generalized estimating equations to assess associations between clinic rollout of both first- and second-line dolutegravir-based ART regimens (dual rollout) and site-level factors.</p><p><strong>Results: </strong>Of 179 surveyed clinics, 175 (98%) participated; 137 (78%) from Africa, 30 (17%) from the Asia-Pacific, and 8 (5%) from Latin America. Most clinics (80%) were in low- or lower-middle-income countries, and there were a mix of primary-, secondary- and tertiary-level clinics. Ninety percent reported rollout of first-line dolutegravir, 59% of second-line, 94% of first- or second-line and 55% of dual rollout. The adjusted odds of dual rollout were higher among tertiary-level (aOR 4.00; 95% CI 1.39 to 11.47) and secondary-level clinics (aOR 3.66; 95% CI 2.19 to 6.11) than in primary-level clinics. Over half (59%) of clinics that introduced first- or second-line dolutegravir-based ART required recent viral load testing before switching to dolutegravir, and 15% performed genotypic resistance testing at switch.</p><p><strong>Conclusions: </strong>Dolutegravir-based ART was rolled out at nearly all IeDEA clinics in LMICs, yet many switched patients to dolutegravir without recent viral load testing and drug resistance testing was rarely performed. Without such testing, drug resistance among patient switching to dolutegravir may go undetected.</p>","PeriodicalId":7502,"journal":{"name":"AIDS","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11562491/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS","FirstCategoryId":"88","ListUrlMain":"https://doi.org/10.1097/QAD.0000000000004007","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: We studied the transition to dolutegravir-containing antiretroviral therapy (ART) at HIV treatment clinics within the International epidemiology Databases to Evaluate AIDS (IeDEA).

Design: Site-level survey conducted in 2020-2021 among HIV clinics in low- and middle-income countries (LMICs).

Methods: We assessed the status of dolutegravir rollout and viral load and drug resistance testing practices for patients on ART switching to dolutegravir-based regimens. We used generalized estimating equations to assess associations between clinic rollout of both first- and second-line dolutegravir-based ART regimens (dual rollout) and site-level factors.

Results: Of 179 surveyed clinics, 175 (98%) participated; 137 (78%) from Africa, 30 (17%) from the Asia-Pacific, and 8 (5%) from Latin America. Most clinics (80%) were in low- or lower-middle-income countries, and there were a mix of primary-, secondary- and tertiary-level clinics. Ninety percent reported rollout of first-line dolutegravir, 59% of second-line, 94% of first- or second-line and 55% of dual rollout. The adjusted odds of dual rollout were higher among tertiary-level (aOR 4.00; 95% CI 1.39 to 11.47) and secondary-level clinics (aOR 3.66; 95% CI 2.19 to 6.11) than in primary-level clinics. Over half (59%) of clinics that introduced first- or second-line dolutegravir-based ART required recent viral load testing before switching to dolutegravir, and 15% performed genotypic resistance testing at switch.

Conclusions: Dolutegravir-based ART was rolled out at nearly all IeDEA clinics in LMICs, yet many switched patients to dolutegravir without recent viral load testing and drug resistance testing was rarely performed. Without such testing, drug resistance among patient switching to dolutegravir may go undetected.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
35 个中低收入国家向基于多罗替拉韦的抗逆转录病毒疗法的过渡:对艾滋病毒护理诊所的全球调查。
目的我们研究了国际艾滋病流行病学评估数据库(IeDEA)中的艾滋病治疗诊所向含多罗替韦的抗逆转录病毒疗法(ART)过渡的情况:设计:2020-2021 年在中低收入国家(LMICs)的 HIV 诊所进行的现场调查:我们评估了多罗替拉韦的推广情况以及接受抗逆转录病毒疗法的患者转用多罗替拉韦治疗方案后的病毒载量和耐药性检测情况。我们使用了广义估计方程来评估诊所同时推广基于多鲁特韦的一线和二线抗逆转录病毒疗法(双线推广)与地点水平因素之间的关联:在 179 家接受调查的诊所中,175 家(98%)参与了调查;其中 137 家(78%)来自非洲,30 家(17%)来自亚太地区,8 家(5%)来自拉丁美洲。大多数诊所(80%)位于低收入或中低收入国家,其中包括初级、二级和三级诊所。90%的诊所报告推出了一线多鲁曲韦,59%的诊所推出了二线多鲁曲韦,94%的诊所推出了一线或二线多鲁曲韦,55%的诊所推出了双线多鲁曲韦。三级诊所(aOR 4.00;95% CI 1.39 至 11.47)和二级诊所(aOR 3.66;95% CI 2.19 至 6.11)的调整后双线推广几率高于一级诊所。在引入基于多鲁曲韦的一线或二线抗逆转录病毒疗法的诊所中,超过一半(59%)的诊所要求在转用多鲁曲韦之前进行近期病毒载量检测,15%的诊所在转用时进行了基因型耐药性检测:结论:在低收入发展中国家,几乎所有的 IeDEA 诊所都推出了基于多鲁曲韦的抗逆转录病毒疗法,但许多诊所在未进行近期病毒载量检测的情况下就将患者转为使用多鲁曲韦,而且很少进行耐药性检测。如果不进行此类检测,转用多鲁特韦的患者的耐药性可能不会被发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
AIDS
AIDS 医学-病毒学
CiteScore
5.90
自引率
5.30%
发文量
478
审稿时长
3 months
期刊介绍: ​​​​​​​​​​​​​​​​​Publishing the very latest ground breaking research on HIV and AIDS. Read by all the top clinicians and researchers, AIDS has the highest impact of all AIDS-related journals. With 18 issues per year, AIDS guarantees the authoritative presentation of significant advances. The Editors, themselves noted international experts who know the demands of your work, are committed to making AIDS the most distinguished and innovative journal in the field. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.
期刊最新文献
SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa. The case for integrating menopause care and HIV management. Weight excess and obesity are associated with binge-eating behaviours in people with HIV. Association of T-cell subtypes with macrophage-specific arterial infiltration in people with HIV. The impact of diabetes mellitus on HIV virologic control: results of the MACS/WIHS combined cohort study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1